1,380 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Infigratinib Cancer	Helsinn Healthcare SA	P1/2	CC (42)
Jab-21822 Cancer	Jacobio Pharmaceuticals Co., Ltd.	P1/2	CC (42)
kl340399 Cancer	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	P1	CC (42)
mk-1200 Cancer	Merck Sharp & Dohme LLC	P1/2	CC (42)
Repaglinide Cancer	PMV Pharmaceuticals, Inc	P1	CC (42)
sph4336 Cancer	Shanghai Pharmaceuticals Holding Co., Ltd	P1/2	CC (42)
Vilastobart Cancer	Xilio Development, Inc.	P1/2	CC (42)
xtx202 Cancer	Xilio Development, Inc.	P1/2	CC (42)
Zeluvalimab Cancer	Amgen	P1	CC (42)
Zimberelimab Cancer	Compugen Ltd	P1	CC (42)
161Tb-NYM032 Cancer	Zhengguo Chen	P1/2	CC (41)
68Ga-NODAGA-SNA006 Cancer	First Hospital of China Medical University	P1/2	CC (41)
a2b395 Cancer	A2 Biotherapeutics Inc.	P1/2	CC (41)
a2b530 Cancer	A2 Biotherapeutics Inc.	P1/2	CC (41)
a2b543 Cancer	A2 Biotherapeutics Inc.	P1/2	CC (41)
a2b694 Cancer	A2 Biotherapeutics Inc.	P1/2	CC (41)
Acit-1 Cancer	Cancer Vaccines Limited	P1/2	CC (41)
ak114 Cancer	Akeso	P1	CC (41)
Dual-Target Antigen-Selected Car-Nk Cancer	Essen Biotech	P1/2	CC (41)
Ebnk-001 Cancer	Essen Biotech	P1/2	CC (41)
Eb-Select Single-Target Car-Nk Cells Cancer	Essen Biotech	P1/2	CC (41)
Fog-001 Cancer	Parabilis Medicines, Inc.	P1/2	CC (41)
gfh276 Cancer	Genfleet Therapeutics (Shanghai) Inc.	P1/2	CC (41)
gk01 Cancer	Beijing Geekgene Technology Co., LTD	P1	CC (41)
hf50 Cancer	HighField Biopharmaceuticals Corporation	P1	CC (41)
Interleukin-15 Cancer	Essen Biotech	P1/2	CC (41)
Interleukin 18 (Recombinant Human Mutein Clone St-067) Cancer	Simcha IL-18, Inc.	P1/2	CC (41)
jk08 Cancer	Salubris Biotherapeutics Inc	P1/2	CC (41)
mk-4716 Cancer	Merck Sharp & Dohme LLC	P1	CC (41)
mk-4884 Cancer	Merck Sharp & Dohme LLC	P1	CC (41)
nv-001 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1	CC (41)
Obinutuzumab Cancer	Simcha IL-18, Inc.	P1/2	CC (41)
Oncolytic Virus Rp1 Cancer	Replimune, Inc.	P1/2	CC (41)
Oncolytic Virus Sdj001 Cancer	West China Hospital	P1	CC (41)
Oncolytic Virus Yd06-1 Cancer	West China Hospital	P1	CC (41)
or502 Cancer	OncoResponse, Inc.	P1/2	CC (41)
Ovv-01 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1	CC (41)
Phox430 Cancer	Phost'In Therapeutics	P1	CC (41)
Psma I&T Cancer	CHU de Quebec-Universite Laval	P1/2	CC (41)
Sarilumab Cancer	University of Southern California	P1/2	CC (41)
Sodium Butyrate Cancer	City of Hope Medical Center	P1	CC (41)
Sodium Propionate Anhydrous Cancer	City of Hope Medical Center	P1	CC (41)
Sotrovimab Cancer	Fred Hutchinson Cancer Center	P1	CC (41)
vb15010 Cancer	Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	P1/2	CC (41)
Vodudeutentan Sodium Cancer	ENB Therapeutics, Inc	P1/2	CC (41)
XP-102 Cancer	Xynomic Pharmaceuticals, Inc.	P1/2	CC (41)
Zovostotug Cancer	OncoResponse, Inc.	P1/2	CC (41)
[111in]-fpi-1967 Cancer	Fusion Pharmaceuticals Inc.	P1/2	CC (40)
[225Ac]-FPI-1966 Cancer	Fusion Pharmaceuticals Inc.	P1/2	CC (40)
64cu-grip b Cancer	Rahul Aggarwal	P1/2	CC (40)

Showing 501 to 550 of 1,379 assets

PreviousPage 11 of 28Next